In a patient with autosomal‑dominant Ehlers‑Danlos syndrome, should I evaluate for a COL1A1‑related disorder such as osteogenesis imperfecta?

Should You Evaluate for COL1A1-Related Disorders in a Patient with Autosomal-Dominant Ehlers-Danlos Syndrome?

Yes, you should consider evaluating for COL1A1/COL1A2-related disorders in patients with autosomal-dominant EDS, particularly if they present with overlapping features of both EDS and osteogenesis imperfecta, as these represent a recognized overlap syndrome that requires different clinical surveillance.

The COL1-Related Overlap Disorder

Recent evidence has established that COL1A1 and COL1A2 variants can cause a distinct overlap syndrome that combines features of both EDS and OI, which doesn't fit neatly into either traditional diagnostic category 1, 2. This is not simply EDS or OI—it's a recognizable clinical entity with unique management needs.

Key Clinical Features Suggesting COL1-Related Overlap:

EDS-predominant features (usually more prominent):

• Joint hypermobility and hyperextensibility
• Skin hyperextensibility and fragility
• Easy bruising
• Abnormal wound healing

OI-related features (typically milder):

• Mildly reduced bone mass
• Occasional fractures (but not the severe fracture burden of classic OI)
• Short stature
• Blue sclerae (variable)

Critical Red Flag: Vascular Fragility

Vascular or arterial fragility has been documented in approximately 27% (4/15) of patients with COL1-related overlap syndrome 1. This is a crucial finding because:

• Some patients were initially diagnosed with hypermobile EDS (hEDS) before vascular complications emerged
• These patients require different surveillance protocols than typical EDS
• The presence of vascular fragility fundamentally changes management and monitoring strategies

When to Test for COL1A1/COL1A2 Variants

Strong Indications for Testing:

1. Mixed phenotype: Patient has features of both EDS and OI that don't fit cleanly into either diagnosis
2. Unexplained short stature in a patient with EDS features
3. Any history of fractures (even occasional) combined with joint hypermobility
4. Vascular complications in someone with an EDS-like presentation
5. Initial diagnosis of hEDS but with atypical features like bone fragility or short stature

Specific Variant Patterns to Understand:

The molecular findings show distinct patterns 1, 2:

• COL1A2 variants more commonly present with EDS-predominant phenotype (9/10 cases)
• COL1A1 frameshift variants more often show OI-predominant features (4/5 cases)
• Glycine substitutions affecting the procollagen N-proteinase cleavage site are particularly associated with this overlap phenotype
• Arginine-to-cysteine variants in COL1A1 can cause classical EDS with vascular fragility

Clinical Pitfalls to Avoid

The hEDS Misdiagnosis Problem

A significant proportion of patients with COL1-related overlap are initially misdiagnosed with hypermobile EDS 1. This is problematic because:

• hEDS is a clinical diagnosis without identified genetic cause
• COL1-related overlap requires genetic confirmation and has different inheritance patterns
• Vascular surveillance is not standard for hEDS but is critical for COL1-related overlap
• Family counseling and recurrence risk calculations differ substantially

Don't Dismiss Variants as "VUS"

One case report highlights a COL1A1 arginine-to-cysteine variant that was originally misclassified as a variant of uncertain significance despite this variant type being well-established as pathogenic for classical EDS with vascular fragility 1. Gene-specific knowledge is essential for proper variant interpretation.

Practical Testing Approach

For patients with suspected COL1-related overlap:

1. Order comprehensive COL1A1 and COL1A2 sequencing (not just targeted panels for classic OI or EDS)

2. Look specifically for:

   • Glycine substitutions near N-proteinase cleavage sites
   • Splice site variants
   • Frameshift variants
   • Arginine-to-cysteine substitutions

3. Biochemical collagen studies can provide supportive evidence:

   • Reduced type I collagen secretion
   • Abnormal collagen structure on dermal biopsy
   • Ultrastructural changes more typical of EDS than OI 2

Management Implications

If COL1-related overlap is confirmed, implement:

• Vascular surveillance protocols (even if no current vascular symptoms)
• Bone density monitoring
• Fracture prevention strategies (though less intensive than classic OI)
• Genetic counseling with accurate recurrence risk (autosomal dominant inheritance)
• Consideration of bisphosphonate therapy if bone density is significantly reduced
• Careful surgical planning given both tissue fragility and potential vascular complications

The Bottom Line

The recognition of COL1-related overlap syndrome means that the traditional separation between OI and EDS is not absolute. Patients with autosomal-dominant EDS features, particularly those with any bone fragility, short stature, or vascular complications, warrant evaluation for COL1A1/COL1A2 variants 1, 2. This is not academic—it changes surveillance, management, and genetic counseling in meaningful ways that affect patient outcomes and quality of life.

The most recent evidence from 2023-2025 consistently demonstrates this overlap exists, is underrecognized, and has clinical consequences when missed 3, 1.